Market Eyes LiveBoston Scientific Corp. (BSX) Stock Rating & Analysis
MELANY's data-driven read on Boston Scientific Corp. · Surgical & Medical Instruments & Apparatus.
Boston Scientific makes less invasive medical devices inserted into the body through small openings or cuts, with products for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal diagnostics, interventional oncology, neuromodulation for chronic pain, and incontinence treatment. It markets to healthcare professionals and institutions globally, with foreign sales making up roughly 36% of total sales.
Why BSX scores 61/100
MELANY scores Boston Scientific Corp. 61/100 by weighing eight factors. Here is how BSX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 20.0x vs sector 22.0x median
- PEG ratio 0.75 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 69%
Direction and relative strength of the recent share-price trend.
- Price +6.5% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
What Wall Street price targets and revisions are signalling.
- Analyst targets 27% upside
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for BSX
- Weak price momentum, trend not yet confirmed, may need more time to set up
Sector and theme context
Boston Scientific Corp. sits in the Healthcare sector theme, which MELANY currently rates 53/100 for strength. Theme strength feeds BSX's momentum and catalyst factors above.
Tracking BSX
Boston Scientific Corp. rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add BSX to your watchlist and get alerted the moment the rating changes.
How MELANY rates BSX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Boston Scientific Corp.'s 61/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about BSX
Is Boston Scientific Corp. (BSX) a buy?
As of 2026-08-20, MELANY rated Boston Scientific Corp. Hold with a composite score of 61/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Boston Scientific Corp.'s MELANY score?
Boston Scientific Corp. (BSX) has a MELANY composite score of 61/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the BSX stock rating calculated?
MELANY scores BSX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Boston Scientific Corp. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Boston Scientific Corp. (BSX) Hold with a composite of 61/100 as of 2026-08-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the BSX stock price forecast?
MELANY does not publish price targets or forecasts for BSX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 61/100 across eight factors for Boston Scientific Corp., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is BSX stock overvalued or undervalued?
MELANY's valuation factor currently reads 65/100 for Boston Scientific Corp., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BSX's read.
What price should I buy BSX at?
MELANY is not flagging a fresh entry for BSX at its current Hold rating, so there is no entry zone to publish right now. Watchlisting BSX in the free app gets you alerted the moment that changes.
What are the risks of buying BSX stock?
The top risks MELANY currently flags for Boston Scientific Corp.: Weak price momentum, trend not yet confirmed, may need more time to set up. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Boston Scientific Corp. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 73/100 for Boston Scientific Corp., and earnings track record, at 75/100. The 61/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will BSX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 33/100 for BSX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this BSX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-20. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores BSX continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
BSX's live rating and alerts are free either way. The app is our flagship.